In a report released on September 14, Robyn Karnauskas from Truist Financial maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $50.00. The company’s shares closed yesterday at $19.90.
According to TipRanks, Karnauskas is a 4-star analyst with an average return of 6.3% and a 50.65% success rate. Karnauskas covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Coherus Biosciences, and Eli Lilly & Co.
In addition to Truist Financial, Arcus Biosciences also received a Buy from Mizuho Securities’s Mara Goldstein in a report issued on September 8. However, on September 5, Bank of America Securities reiterated a Hold rating on Arcus Biosciences (NYSE: RCUS).
RCUS market cap is currently $1.53B and has a P/E ratio of -5.21.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RCUS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Read More on RCUS: